GT200000224A - COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS. - Google Patents

COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS.

Info

Publication number
GT200000224A
GT200000224A GT200000224A GT200000224A GT200000224A GT 200000224 A GT200000224 A GT 200000224A GT 200000224 A GT200000224 A GT 200000224A GT 200000224 A GT200000224 A GT 200000224A GT 200000224 A GT200000224 A GT 200000224A
Authority
GT
Guatemala
Prior art keywords
composition
treatment
growth factor
inhibiting agent
damaged fabrics
Prior art date
Application number
GT200000224A
Other languages
Spanish (es)
Inventor
Michael John Davies
Jonathan Paul Huggins
Fraser Stuart Mcintosh
Nicholas Laurence Occleston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000224A publication Critical patent/GT200000224A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION, EN PARTICULAR, A UNA COMPOSICION FARMACEUTICA. LA PRESENTE INVENCION TAMBIEN SE REFIERE A USOS DE ESA COMPOSICION, EN PARTICULAR, PARA EL TRATAMIENTO DE TEJIDOS DAÑADOS. DE ACUERDO CON LA PRESENTE INVENCION LOS TEJIDOS DAÑADOS TALES COMO LAS HERIDAS, PUEDEN TRATARSE DE FORMA MAS EFICAZ SI SE USA UNA COMBINACION DE UN FACTOR DE CRECIMIENTO COMO UN POLIPEPTIDO Y UN AGENTE INHIBIDOR, UNA PROTEASA O SU DERIVADO ESTANDO INVOLUCRADO ESPECIFICAMENTE CON LA PROTEINA EN DERREDOR DE LA HERIDA. LA COMBINACION DEL AGENTE INHIBIDOR Y EL FACTOR DE CRECIMIENTO ACTUAN SINERGICAMENTE. TIPICAMENTE PARA MEZCLAS TOPICAS O MEZCLAS INYECTADAS LOCALMENTE, LA RELACION RELATIVA ENTRE EL AGENTE INHIBIDOR Y EL FACTOR DE CRECIMIENTO PUEDE ESTAR COMPRENDIDA ENTRE 1000:1 Y 1:1. DE ACUERDO A LA INVENCION SE PROPORCIONA EL USO DE UNA COMPOSICION PARA EL TRATAMIENTO MEDICO DE HERIDAS.THIS INVENTION REFERS TO A COMPOSITION, IN PARTICULAR, A PHARMACEUTICAL COMPOSITION. THIS INVENTION ALSO REFERS TO USES OF THAT COMPOSITION, IN PARTICULAR, FOR THE TREATMENT OF DAMAGED FABRICS. IN ACCORDANCE WITH THIS INVENTION DAMAGED FABRICS SUCH AS INJURED, CAN BE TREATED MORE EFFECTIVELY IF A COMBINATION OF A GROWTH FACTOR IS USED AS A POLYPEPTIDE AND AN INHIBITING AGENT, A PROTEASE OR ITS DERIVATIVE BEING INVOLVED BY THE SPECIFIED DURING THE WOUND. THE COMBINATION OF THE INHIBITING AGENT AND THE GROWTH FACTOR ACT SYNERGICALLY. Typically for topically mixed or locally injected blends, the relative relationship between the inhibiting agent and the growth factor may be understood between 1000: 1 and 1: 1. ACCORDING TO THE INVENTION, THE USE OF A COMPOSITION FOR MEDICAL WOUND TREATMENT IS PROVIDED.

GT200000224A 1999-12-29 2000-12-22 COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS. GT200000224A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Publications (1)

Publication Number Publication Date
GT200000224A true GT200000224A (en) 2002-06-15

Family

ID=10867127

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000224A GT200000224A (en) 1999-12-29 2000-12-22 COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS.

Country Status (12)

Country Link
EP (1) EP1242120A2 (en)
JP (1) JP2003519193A (en)
AR (1) AR027122A1 (en)
AU (1) AU1878201A (en)
CA (1) CA2395487A1 (en)
CO (1) CO5271671A1 (en)
EC (1) ECSP003859A (en)
GB (1) GB9930768D0 (en)
GT (1) GT200000224A (en)
PE (1) PE20011095A1 (en)
UY (1) UY26514A1 (en)
WO (1) WO2001049309A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1326980B1 (en) * 2000-10-16 2008-03-19 Genentech, Inc. Methods of treatment using wisp polypeptides
CN100509055C (en) 2001-07-27 2009-07-08 奥索洛吉艾斯有限公司 Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
WO2003029819A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Method of screening preventive/remedy for bone/joint diseases
JP2006514822A (en) 2002-07-02 2006-05-18 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Thrombin peptide derivative
JP5044829B2 (en) 2003-12-31 2012-10-10 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Pharmaceutical composition for thrombin peptide derivatives
CA2623531C (en) * 2005-10-07 2013-12-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Matrix metalloproteinase 11 vaccine
KR20100027091A (en) * 2006-11-15 2010-03-10 코다 테라퓨틱스, 인크. Improved methods and compositions for wound healing
KR101629504B1 (en) * 2014-04-14 2016-06-10 주식회사 엘지생활건강 Composition for improving skin conditions containing a combination of cytokines
AU2018254555A1 (en) * 2017-04-21 2019-10-31 Intrexon Corporation Delivery of autologous cells comprising matrix metalloproteinase for treatment of scleroderma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (en) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd Novel composition for external use
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
AR027122A1 (en) 2003-03-12
WO2001049309A2 (en) 2001-07-12
CA2395487A1 (en) 2001-07-12
ECSP003859A (en) 2002-09-27
EP1242120A2 (en) 2002-09-25
WO2001049309A3 (en) 2002-02-28
JP2003519193A (en) 2003-06-17
PE20011095A1 (en) 2001-10-27
GB9930768D0 (en) 2000-02-16
AU1878201A (en) 2001-07-16
CO5271671A1 (en) 2003-04-30
UY26514A1 (en) 2001-07-31

Similar Documents

Publication Publication Date Title
ES2167061T3 (en) DOSAGE FORMS TO IMPROVE ERECTILE DYSFUNCTION IN MALE SEX PATIENTS.
AR010701A1 (en) A TISSUE COMPOSITION DUE TO OXIDATION OF KERATIN FIBERS AND A TINTING PROCEDURE USING THIS COMPOSITION
CO2021000174A2 (en) Topical compositions for pain relief
BR0311939A (en) pharmaceutical composition, method for treating inflammation in a mammal and use of a protective tissue cytokine
AR005281A1 (en) ORAL PHARACEUTICAL COMPOSITION, PROCEDURES FOR ITS MANUFACTURE AND USE OF THAT PHARMACEUTICAL COMPOSITION FOR THE PREPARATION OF MEDICINES. .
ES2161085T3 (en) FORMULATIONS CONTAINING OXALIPLATIN.
ECSP034444A (en) DERIVATIVES OF 4-AMINO-6-PHENYL-PIRROLO (2,3-D) PYRIMIDINE
NI200800169A (en) USE OF BENZO-FUSED HETEROCYCLIC SULFAMID DERIVATIVES FOR THE TREATMENT OF PAIN
ES2157601T3 (en) USE OF ANTI-MICROTUBLE AGENTS TO TREAT OR PREVENT MULTIPLE SCLEROSIS.
AR009676A1 (en) READY-TO-USE COMPOSITION FOR KEEPING BY OXIDATION OF KERATIN FIBERS, HAVING PROCEDURE USING THIS COMPOSITION, AND DEVICE FOR SEVERAL COMPARTMENTS.
ES2055677T1 (en) PROCEDURE FOR OBTAINING A COMPOSITION FOR THE TREATMENT OF ERECTILE DYSFUNCTION.
AR024813A1 (en) TREATMENT AND COMPOSITION TO ACHIEVE ANTI-AGING SKIN BENEFITS BY ACTIVATION OF PROTEASE OF THE CORNEE STRATUM.
GT200000224A (en) COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS.
AR012671A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PROPHYLAXIS OF THE CONSTIPATION, THE USES OF SUCH COMPOSITIONS AND THE PROCESSES TO PREPARE THEM
ES2188426B1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS AND OTHER DERMOPATIAS.
PE20020348A1 (en) EXEMESTAN AS A CHEMOPREVENTIVE AGENT
AR019699A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DYSFUNCTION OF THE EVACUATION AND USE OF THE SAME FOR THE PREPARATION OF A THERAPEUTIC AGENT
ES2137044T3 (en) USE OF OXAZOLIDINONE DERIVATIVES AS ANTIPENETRANT AGENTS IN A COSMETIC AND / OR DERMATOLOGICAL COMPOSITION.
ES2171589T3 (en) SOLID PHARMACEUTICAL COMPOSITIONS ANHYDRA FOR VAGINAL USE.
ES2174337T3 (en) TOPICAL USE OF KAPPA OPIOID AGONISTS FOR THE TREATMENT OF EYE PAIN.
ES2188995T3 (en) USE OF AN INHIBITOR OF THE H +, K + -ATPASA IN THE TREATMENT OF NASAL POLYPS.
AR049210A1 (en) COMPOSITION WITH TENSIOACTIVE COMPOUNDS, FOR THE REDUCTION OF FAT LOCATED IN THE HUMAN BODY AND A METHOD FOR REDUCING SUCH FAT LOCALIZED
AR006892A1 (en) USE OF FORMS OF HYALURONIC ACID (HA) FOR THE TREATMENT OF CANCER
BR9810981A (en) Yohimbine and arginine-containing medication to treat erectile dysfunction
ES2133003T3 (en) USE OF AT LEAST ONE GLYCOL AS A SOLUBILIZING AGENT OF MELATONIN IN WATER AND COMPOSITIONS CONTAINING THEM.